Product Description: DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is about 3-10-fold more potent than the parent agent Maytansine, with IC50s ranging from 0.003 to 0.01 nM for DM1-SMe in a panel of human tumor cell lines[1].
Applications: Cancer-programmed cell death
Formula: C36H50ClN3O10S2
References: [1]Wood AC, et al. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013;60(11):1860-1867. /[2]Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41(1):98-107.
CAS Number: 138148-68-2
Molecular Weight: 784.38
Compound Purity: 98.16
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: ADC Cytotoxin;Microtubule/Tubulin